11-17-2007, 06:36 PM
Clinical efficacy of zonisamide in Lennox-Gastaut syndrome: Korean multicentric experience.
Brain Dev. 2007 Oct 22;
Authors: You SJ, Kang HC, Kim HD, Lee HS, Ko TS
Purpose: To evaluate the efficacy and safety of zonisamide (ZNS) as long-term adjunctive therapy in children with Lennox-Gastaut syndrome (LGS). Method: We evaluated the seizure frequency, cognitive outcomes, and side effects of 62 LGS patients maintained on ZNS for at least 12 months in three tertiary centers. Results: Of the 62 LGS patients maintained on ZNS, 3 (4.8%) had 100% seizure control; 14 (22.6%) had >75% to <100% reduction in seizure frequency; 15 (24.2%) had >50% to <75% reduction in seizure frequency; 6 (9.7%) had >0% to <50% reduction in seizure frequency, and 24 (38.7%) had no seizure reduction. Seizure outcomes were not related to seizure types or etiologies. Adverse events included somnolence and anorexia, but all were transient and successfully managed by careful follow-up. Conclusion: Our results indicate that adjunctive treatment with ZNS is safe and effective in pediatric LGS patients.
PMID: 17959327 [PubMed - as supplied by publisher] (Source: Brain & Development)
Posted on Mon, 22 Oct 2007 04:00:00 +0100 at http://www.ncbi.nlm.nih.gov/entrez/query...t=Abstract
Author: Brain & Development
Comments: http://www.medworm.com/rss/comments.php?id=980439
Brain Dev. 2007 Oct 22;
Authors: You SJ, Kang HC, Kim HD, Lee HS, Ko TS
Purpose: To evaluate the efficacy and safety of zonisamide (ZNS) as long-term adjunctive therapy in children with Lennox-Gastaut syndrome (LGS). Method: We evaluated the seizure frequency, cognitive outcomes, and side effects of 62 LGS patients maintained on ZNS for at least 12 months in three tertiary centers. Results: Of the 62 LGS patients maintained on ZNS, 3 (4.8%) had 100% seizure control; 14 (22.6%) had >75% to <100% reduction in seizure frequency; 15 (24.2%) had >50% to <75% reduction in seizure frequency; 6 (9.7%) had >0% to <50% reduction in seizure frequency, and 24 (38.7%) had no seizure reduction. Seizure outcomes were not related to seizure types or etiologies. Adverse events included somnolence and anorexia, but all were transient and successfully managed by careful follow-up. Conclusion: Our results indicate that adjunctive treatment with ZNS is safe and effective in pediatric LGS patients.
PMID: 17959327 [PubMed - as supplied by publisher] (Source: Brain & Development)
Posted on Mon, 22 Oct 2007 04:00:00 +0100 at http://www.ncbi.nlm.nih.gov/entrez/query...t=Abstract
Author: Brain & Development
Comments: http://www.medworm.com/rss/comments.php?id=980439